12:00 AM
 | 
Jan 24, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Peru-15: Began Phase IIb trial

Avant Immunotherapeutics Inc. (AVAN), Needham, Mass.
Product: Peru-15
Business: Infectious diseases
Therapeutic category: Immune stimulation
Target:...

Read the full 66 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >